Related Experiment Video
Updated: Jun 25, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
Clozapine-induced cardiotoxicity: a clinical update
Jamie J Layland1, Danny Liew, David L Prior
1St Vincent's Hospital, Melbourne, VIC, Australia. jamie_layland@health.qld.gov.au
Clozapine can cause serious heart problems like myocarditis in schizophrenia patients. Early detection using echocardiography and B-type natriuretic peptide levels is crucial for managing clozapine-induced cardiotoxicity.
Area of Science:
- Cardiology
- Psychiatry
- Pharmacology
Background:
- Clozapine is essential for treatment-resistant schizophrenia.
- Cardiac complications, including myocarditis, cardiomyopathy, and pericarditis, are known risks.
- Diagnosing clozapine-induced myocarditis is challenging due to non-specific symptoms.
Purpose of the Study:
- To review diagnostic tools for clozapine-induced cardiotoxicity.
- To highlight the importance of early detection and management.
- To discuss the role of echocardiography and B-type natriuretic peptide.
Main Methods:
- Review of literature on clozapine cardiotoxicity.
- Discussion of diagnostic modalities.
- Emphasis on clinical suspicion and supportive care.
Main Results:
- Myocarditis is a significant, though often subtle, cardiac risk of clozapine.
- Transthoracic echocardiography is a practical diagnostic aid.
- B-type natriuretic peptide may aid in evaluation and future screening.
Conclusions:
- Prompt recognition and management of clozapine cardiotoxicity are vital.
- Cessation of clozapine and supportive care are the primary treatments.
- Further research into screening asymptomatic patients is warranted.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Psychosis: Goals of Pharmacotherapy
Cardiomyopathy VI: Nursing Management
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
